10x Genomics (NASDAQ:TXG) has built a reputation as a trailblazer in recent years, with cutting-edge single-cell and spatial technologies. The firm's Chromium, Visium and Xenium platforms have ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Additionally, the company’s Chromium installations exceeded expectations, further supporting the Buy rating. These factors together underpin the positive long-term outlook for 10x Genomics.

Specifically, the instrument and consumables revenues were higher than anticipated, with significant contributions from both Chromium and ... showcasing 10x Genomics’s ability to expand its ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Increased cumulative instruments sold to more than 7,000 instruments as of the end of 2024, which includes over 5,800 Chromium instruments ... Co-founder and CEO of 10x Genomics.

and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive ...